Who
Gregory M. Sullivan
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Tonix Pharmaceuticals Holding.
In numbers
- Trades disclosed
- 49
- Buys
- 8
- Sells
- 0
- Bought
- $256K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Jun 2014
- Last trade
- 24 Feb 2026
- Last filed
- 26 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,012 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,011 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,012 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,011 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,017 at $0.00 | filing |
| 25 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,017 at $0.00 | filing |
| 5 Feb 2025filed 27 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $00.11 at $1.47 | filing |
| 27 Feb 2024filed 29 Feb 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —358,000 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —358,000 at $0.00 | filing |
| 23 Feb 2023filed 24 Feb 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 23 Feb 2023filed 24 Feb 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,250,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,250,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,250,000 at $0.00 | filing |
| 15 Feb 2022filed 17 Feb 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,250,000 at $0.00 | filing |
| 30 Jun 2021filed 11 Feb 2022 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code A | $21K36,496 at $0.58 | filing |
| 23 Feb 2021filed 25 Feb 2021 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 23 Feb 2021filed 25 Feb 2021 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 7 Jan 2021filed 25 Feb 2021 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code A | $21K41,322 at $0.51 | filing |
| 17 Aug 2020filed 19 Aug 2020 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $21K20,000 at $1.03 | filing |
News
Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine CandidateTNXP · rttnews.com · 15 Oct 2026Tonix Pharmaceuticals Begins Building Lyme Disease Drug Facility in Hamilton, MontanaTNXP · matr.net · 12 Oct 2026
0 headlines in the last 90 days name Gregory M. Sullivan; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.